Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.29 USD | +7.50% | +14.16% | -27.53% |
May. 10 | Transcript : Protalix BioTherapeutics, Inc., Q1 2024 Earnings Call, May 10, 2024 | |
May. 10 | Protalix BioTherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Business Summary
Number of employees: 208
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Recombinant Therapeutic Proteins
100.0
%
| 48 | 100.0 % | 38 | 100.0 % | -19.50% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Global
56.3
%
| 22 | 46.9 % | 22 | 56.3 % | -3.33% |
United States
26.5
%
| 12 | 26.0 % | 10 | 26.5 % | -18.08% |
Brazil
16.7
%
| 9 | 19.8 % | 6 | 16.7 % | -32.29% |
Italy
0.5
%
| 3 | 7.2 % | 0 | 0.5 % | -94.50% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Dror Bashan
CEO | Chief Executive Officer | 57 | 19-06-29 |
Eyal Rubin
DFI | Director of Finance/CFO | 48 | 19-07-21 |
Yael Hayon
CTO | Chief Tech/Sci/R&D Officer | 41 | 20-07-04 |
Yaron Naos
COO | Chief Operating Officer | 60 | 03-12-31 |
Gina Balderas
PRN | Corporate Officer/Principal | - | - |
Fellous Yael
HRO | Human Resources Officer | - | 22-07-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Pol Boudes
BRD | Director/Board Member | 67 | 19-11-30 |
Gwen Melincoff
BRD | Director/Board Member | 72 | 19-11-30 |
Aharon Schwartz
BRD | Director/Board Member | 80 | 14-10-31 |
Amos Bar Shalev
BRD | Director/Board Member | 71 | 08-06-30 |
Eliot Forster
CHM | Chairman | 58 | 23-09-13 |
Shmuel Ben Zvi
BRD | Director/Board Member | 64 | 22-06-29 |
Dror Bashan
CEO | Chief Executive Officer | 57 | 19-06-29 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 73,316,084 | 62,627,738 ( 85.42 %) | 0 | 85.42 % |
Company contact information
Protalix Biotherapeutics, Inc.
2 University Plaza Suite 100
07601, Hackensack
+972 4 902 8100
http://www.protalix.comSector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-27.53% | 94.58M | |
+64.23% | 62.59B | |
-2.31% | 41.18B | |
+45.55% | 40.29B | |
-8.29% | 27.9B | |
+11.97% | 26.21B | |
-21.16% | 19.09B | |
+7.54% | 13.08B | |
+25.72% | 12.26B | |
+27.17% | 12.05B |
- Stock Market
- Equities
- PLX Stock
- Company Protalix BioTherapeutics, Inc.